Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2011 3
2012 4
2013 5
2014 5
2015 8
2016 3
2017 2
2018 3
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of CDK5 Inhibitors through Structure-Guided Approach.
Khair NZ, Lenjisa JL, Tadesse S, Kumarasiri M, Basnet SKC, Mekonnen LB, Li M, Diab S, Sykes MJ, Albrecht H, Milne R, Wang S. Khair NZ, et al. Among authors: kumarasiri m. ACS Med Chem Lett. 2019 Mar 20;10(5):786-791. doi: 10.1021/acsmedchemlett.9b00029. eCollection 2019 May 9. ACS Med Chem Lett. 2019. PMID: 31098000 Free PMC article.
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Philip S, Kumarasiri M, Teo T, Yu M, Wang S. Philip S, et al. Among authors: kumarasiri m. J Med Chem. 2018 Jun 28;61(12):5073-5092. doi: 10.1021/acs.jmedchem.7b00901. Epub 2018 Jan 9. J Med Chem. 2018. PMID: 29266937 Review.
CDK5 in oncology: recent advances and future prospects.
Lenjisa JL, Tadesse S, Khair NZ, Kumarasiri M, Yu M, Albrecht H, Milne R, Wang S. Lenjisa JL, et al. Among authors: kumarasiri m. Future Med Chem. 2017 Oct;9(16):1939-1962. doi: 10.4155/fmc-2017-0097. Epub 2017 Oct 27. Future Med Chem. 2017. PMID: 29076761 Review.
Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
Tadesse S, Bantie L, Tomusange K, Yu M, Islam S, Bykovska N, Noll B, Zhu G, Li P, Lam F, Kumarasiri M, Milne R, Wang S. Tadesse S, et al. Among authors: kumarasiri m. Br J Pharmacol. 2018 Jun;175(12):2399-2413. doi: 10.1111/bph.13974. Epub 2018 May 8. Br J Pharmacol. 2018. PMID: 28800675 Free PMC article.
In Search of Novel CDK8 Inhibitors by Virtual Screening.
Kumarasiri M, Teo T, Yu M, Philip S, Basnet SK, Albrecht H, Sykes MJ, Wang P, Wang S. Kumarasiri M, et al. J Chem Inf Model. 2017 Mar 27;57(3):413-416. doi: 10.1021/acs.jcim.6b00711. Epub 2017 Feb 16. J Chem Inf Model. 2017. PMID: 28191946
Targeting CDK9: a promising therapeutic opportunity in prostate cancer.
Rahaman MH, Kumarasiri M, Mekonnen LB, Yu M, Diab S, Albrecht H, Milne RW, Wang S. Rahaman MH, et al. Among authors: kumarasiri m. Endocr Relat Cancer. 2016 Dec;23(12):T211-T226. doi: 10.1530/ERC-16-0299. Epub 2016 Aug 31. Endocr Relat Cancer. 2016. PMID: 27582311 Review.
Three-dimensional QSAR analysis and design of new 1,2,4-oxadiazole antibacterials.
Leemans E, Mahasenan KV, Kumarasiri M, Spink E, Ding D, O'Daniel PI, Boudreau MA, Lastochkin E, Testero SA, Yamaguchi T, Lee M, Hesek D, Fisher JF, Chang M, Mobashery S. Leemans E, et al. Among authors: kumarasiri m. Bioorg Med Chem Lett. 2016 Feb 1;26(3):1011-1015. doi: 10.1016/j.bmcl.2015.12.041. Epub 2015 Dec 12. Bioorg Med Chem Lett. 2016. PMID: 26733473 Free PMC article.
36 results